Myonex’s Post

With our recent announcement of our agreement to acquire CREAPHARM BIO&PHARMA’s clinical packaging & distribution and commercial packaging business and bioservices, comes expanded packaging solutions for your projects: ☑️ ATMPs Supply Chain Management: Expert handling of biotherapies, ensuring integrity from storage to distribution. ☑️ Global Reach, Local Touch: With an extended global presence, we're bringing you closer to your markets while maintaining that personalized service you love. ☑️ Streamlined Efficiency: Bundle your packaging needs with Myonex’s other services for a smoother, more cost-effective process. Let's discuss how our new combined capabilities can elevate your next project’s clinical trial supply: https://bit.ly/48TKOuL The completion of this transaction is subject to regulatory approvals. #Myonex #PackagingExcellence #Innovation #ClinicalTrialsPackaging #Clinical Trials #ContractPackaging

Embark on an exciting entrepreneurial journey by starting your own B2B pharma franchise company with Zoeci9a Healthcare. Zoeci9a Healthcare, a leading name in the pharmaceutical industry, offers a lucrative franchise model designed to empower aspiring business owners. Here’s what you can expect: ✅ Comprehensive Product Portfolio: Gain access to a wide range of high-quality pharmaceutical products, including generics, specialty medicines, and over-the-counter drugs. ✅ Proven Business Model: Benefit from a successful and scalable business model that ensures growth and profitability. ✅ Training and Support: Receive extensive training and ongoing support from Zoeci9a Healthcare’s experienced team, covering everything from marketing strategies to regulatory compliance. ✅ Brand Recognition: Leverage the strong brand reputation of Zoeci9a Healthcare to establish credibility and trust in the market. ✅ Exclusive Rights: Enjoy exclusive territorial rights, giving you the advantage of operating without competition in your designated area. ✅ Marketing Assistance: Access to professional marketing materials and promotional strategies to help you effectively reach and engage with your target audience. ✅ Affordable Investment: Start your venture with a low initial investment and benefit from high returns on investment. #B2BPharmaFranchise #Zoeci9aHealthcare #PharmaceuticalFranchise #StartYourOwnBusiness #HealthcareEntrepreneurship #PharmaIndustry #FranchiseOpportunities #BusinessGrowth #PharmaProducts #ExclusiveTerritorialRights #MarketingSupport #LowInvestmentHighReturns #PharmaBusinessModel #HealthcareSuccess

📢 CREAPHARM is excited to announce we have reached an agreement for the #acquisition of CREAPHARM GROUP's Clinical Packaging & Distribution, Commercial Packaging business and bioservices, by Myonex. The completion of this transaction is subject to regulatory approvals. 💡 Myonex, a global clinical trial supply company, is focused on speed, flexibility, reliability and quality in clinical trials with expertise in drug sourcing, clinical packaging, labeling and distribution, and ancillary equipment and supplies. 🔗 With complementary strengths and cultural alignment, we will be better together in scale and #capabilities while keeping #flexibility to support our trusted clients, who will benefit from enhanced #global service offerings. 📰 Read the Press Release about this exciting announcement in the first link in comment #ClinicalTrialSupply #CommercialPackaging #ATMPSupplyChain

The first half of 2024 has been nothing short of transformative for the #pharma sector! 💊 We've witnessed major turnarounds with landmark rulings like the Supreme Court's decision on electoral bonds, significant #acquisitions reshaping the industry, and strategic #global collaborations advancing drug development. The #government's Production-Linked Incentive (PLI) scheme has fueled unprecedented growth, with #investments skyrocketing to INR 28,328 Cr.  Regulatory changes, such as the rollout of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), aim to enhance industry integrity. Notable CEO appointments and expansions into new healthcare sectors by companies like MANKIND PHARMA LTD and Roche India showcase the industry's dynamic nature. 🩺 As we move into the second half of the year, expect more groundbreaking developments on the #horizon.💡 🔗Read the Article - https://lnkd.in/d4CPQsQe 🖊️Writes - Nikita Saha 🌐 Stay Informed with our Latest Stories – https://lnkd.in/gMUPB2Zp  #Pharma #Healthcare #Innovation #Acquisitions #IPOs #Regulations #Leadership #PharmaGrowth

Last week we were thrilled to announce CREAPHARM GROUP reached an #agreement with Myonex to acquire its clinical & commercial packaging and bioservices business*.  What does it really mean? 🎯 Better together in #scale and #capabilities while keeping #flexibility to support each customer’s project  🎯 Enhanced global service #offerings: take a look at what’s coming up for your Clinical Trial Supply Management #CTSM   ✔ A genuine comparator drug sourcing service  ✔ Ancillary equipment and supplies ✔ QP oversight (UK) & IOR services, facilitating your UK clinical trials  ✔ Additional clinical distribution pathways to serve your global clinical supply chain  ✔ CTRx™, a combination of prescription card services, global pharmacy dispensing, and centralized local drug supply in a single solution    🎯 And obviously, still serving your clinical packaging and labelling needs, delivering a high-level pharmaceutical support, handling your commercial packaging operations and managing your ATMPs Supply Chain . * The completion of this transaction is subject to regulatory approvals 👇 See what Myonex CEO, James Lovett, had to say about...

While awaiting approval to launch a new product, a large pharmaceutical company identified a need to revisit their market access strategy due to various evolving external factors that could require adjustments in their launch approach. Tap the link to read how Vynamic helped this client assess those factors; refresh their strategy; identify, implement, and recommended adjustments; and implement an ongoing performance monitoring framework that ensured they would remain nimble with the evolving market. https://lnkd.in/ezr9uigm

The Impact of 340B on Commercial Contracts and Using Data to Close the Gross to Net Gap: The 340B Drug Pricing Program has experienced explosive growth, leaving pharma companies struggling to understand its full impact and how it affects their market access strategies, market dynamics and contract negotiations. Pharma companies can negotiate better commercial contracts to help minimize duplicate discounts between commercial rebates and 340B. Knowing the data around your contracts can help address the ever-expanding gap between gross to net pricing and prevent revenue leakage. Join experts as they highlight the 340B Drug Pricing Program and how the discount program is handled by commercial contracts. They’ll discuss the impact of a lack of data on revenue leakage and the importance of leveraging a data-driven solution to protect the bottom line. You’ll learn: * The impact of the 340B Drug Pricing Program on pharma companies. * How commercial contracts do (and don’t) account for 340B discounts. * The effect that incomplete data sets can have on commercial contracts. * Best practices for negotiating commercial contracts with PBMs. * How a data-driven solution can lead to more empowered negotiations. Request Free!

Wow yet another wonderful year for GMPharma Ltd... the 1st of December comes again and we are 6 years old today. Our mission, to get critical medicines to market has accelerated at pace this year for our clients - moving from early stages through clinical supplies to scale-up - and preparing for launch in the very near future. This directional leadership has been built on the huge strengths in demonstrated delivery, previously achieved by Helen and Gordon. Delivery in a range of pharmaceutical dosage forms including OSD and Inhalation, however now targeting an expanded number of disease states. Developing novel drug device combination products is another exciting programme for GMPharma, supporting early developments. We continue to hold faith with our principles - set in year one - around consultancy, teaching and STEM activities and charity support, and the nature of the people we work with. The criticality of developing sustainable medicines has been a key feature for us as the focus continues to ramp up with the global challenges for the environment. Given the wealth and depth in our client base, our variety of consultancy work has again increased tremendously over the period, and we are lucky that we still work with "cool dynamic people... on very exciting projects”. We have continued with legal, patent, due diligence and Private Equity activities. Also. working with start ups and spin off organisations; with Gordon becoming Chairman of a Board as well. Additionally, as organisations restructure globally, we help colleagues move from employment to self employment; sharing our success criteria to assist in this big step. The amazing adventure continues, we are having so much fun, but look to continue to help people fighting for breath and improving their health and well-being in a modern digital world… inspiring people to realise and reach their potential, support our National Healthcare Professionals and Charitable organisations. #gmpharma #medicines #pharmaceuticaldevelopment #researchanddevelopment #inhaledprodutdevelopment

Have you ever wondered how you can determine whether a potential partner is right for you? 💡 A lot of people and organizations find themselves in situations where they have signed off to a collaboration that essentially adds no value them. 🛑 Most often that not it is because they did not know how to evaluate whether their pharma partners are the right fit. 💊 What if we told you that there is a comprehensive framework that you can use to avoid these lose-win relationships and ensure that there is mutual benefit in all partnerships you engage in. 🤝 Learn more here>>>> https://lnkd.in/dfkJ988m #collaboration #pharmacy #pharmaceuticals #pharma